Published by Global Banking & Finance Review®
Posted on May 12, 2025
1 min readLast updated: January 23, 2026
Add as preferred source on Google
Bayer will reduce its German agriculture operations by 2028 due to competition from Asian generics and regulatory challenges, impacting jobs in Frankfurt and Dormagen.
FRANKFURT (Reuters) -Bayer said on Monday it would shrink the Crop Science division's production, research and development activities in Germany, citing pressure from cheap generic products, stricter regulation and export barriers.
"These steps are urgently needed to counteract the significant overcapacity and a hopeless price competition with generics manufacturers from Asia," the company said in a statement.
It also cited "increasing regulatory restrictions and national export barriers" in a bid to focus on "strategic, innovative technologies."
Among the cutbacks, Bayer seeks to end its activities in Frankfurt, where it produces and develops herbicides with about 500 staff, after the end of 2028.
Activities there would be sold or relocated, Bayer said.
At the Dormagen site, production of various generic active ingredients will be gradually stopped by the end of 2028, impacting about 200 positions of the nearly 1,200 employees.
"We want to find viable solutions for our colleagues together with employee representatives," Bayer added.
(Reporting by Ludwig Burger, editing by Thomas Seythal)
The article discusses Bayer's decision to reduce its agriculture activities in Germany due to competition from Asian generics and regulatory challenges.
Bayer is scaling back due to pressure from cheap generic products from Asia, stricter regulations, and national export barriers.
Bayer plans to end herbicide production and development at its Frankfurt site by 2028, impacting about 500 staff.
Explore more articles in the Headlines category
